-
May 20, 2026 11:30 UTC
leadership
materiality 0.35
neutral
item 5.02
Celcuity appoints Charles R. Romp to board; board expands from 7 to 8
Board expanded from 7 to 8 members; Charles R. Romp appointed as director effective Feb 11, 2026.
-
May 18, 2026 20:05 UTC
other_material
materiality 0.50
neutral
item 5.02item 5.07item 9.01
Celcuity stockholders approve 2026 equity plan (3M shares) and amended ESPP at annual meeting
Stockholders approved the 2026 Stock Incentive Plan authorizing 3,000,000 shares of common stock for equity awards.
-
May 14, 2026 20:05 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Celcuity reports Q1 net loss $52.8M; VIKTORIA-1 hits primary endpoint in PIK3CA mutant
Net loss $52.8M ($0.97/share) vs $37.0M ($0.86/share) in Q1 2025; non-GAAP adjusted net loss $46.8M ($0.86).
-
May 01, 2026 23:59 UTC
other_material
materiality 0.85
positive
item 7.01item 8.01item 9.01
Celcuity Phase 3 VIKTORIA-1 PIK3CA mutant cohort meets primary endpoint with significant PFS improvement
Gedatolisib triplet (plus fulvestrant and palbociclib) showed statistically significant PFS improvement vs alpelisib+fulvestrant.
-
Mar 25, 2026 23:59 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Celcuity reports Q4 loss $0.97/share; FDA grants Priority Review for gedatolisib, PDUFA July 17, 2026
Net loss Q4 $51.0M ($0.97), FY $177.0M ($3.79); adjusted net loss Q4 $38.4M ($0.73), FY $150.8M ($3.22).
-
Feb 12, 2026 23:59 UTC
leadership
materiality 0.40
positive
item 5.02item 7.01item 9.01
Celcuity appoints Charles Romp to board of directors; brings commercial oncology expertise
Charles (Chip) R. Romp appointed to board, effective Feb 11, 2026; board size increased from 7 to 8.
-
Nov 17, 2025 23:59 UTC
regulatory
materiality 0.90
positive
item 7.01item 8.01item 9.01
Celcuity completes NDA submission to FDA for gedatolisib in HR+/HER2- advanced breast cancer under RTOR program
NDA submitted for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer.
-
Nov 12, 2025 23:59 UTC
earnings
materiality 0.65
neutral
item 2.02item 9.01
Celcuity Q3 net loss $43.8M; gedatolisib NDA on track for Q4 2025
Q3 net loss $43.8M ($0.92 loss per share) vs $29.8M ($0.70 loss) in prior year.
-
Oct 20, 2025 23:59 UTC
other_material
materiality 0.90
positive
item 7.01item 8.01item 9.01
Phase 3 VIKTORIA-1 data: gedatolisib triplet reduces progression risk by 76% in HR+/HER2- ABC
Median PFS 9.3mo for gedatolisib triplet vs 2.0mo for fulvestrant (HR=0.24); incremental 7.3mo improvement.
-
Sep 10, 2025 23:59 UTC
debt
materiality 0.85
positive
item 1.01item 2.03item 3.02item 7.01item 9.01
Celcuity upsizes senior secured facility to $500M, receives $30M immediate funding
Total facility increased to $500M ($350M committed + $150M discretionary); $30M funded, total outstanding $130M.
-
Aug 14, 2025 23:59 UTC
earnings
materiality 0.85
positive
item 2.02item 9.01
Celcuity reports Phase 3 gedatolisib milestone; NDA filing on track for Q4 2025
Phase 3 VIKTORIA-1: gedatolisib triplet reduced risk of progression/death by 76% (HR=0.24); median PFS 9.3 mo vs 2.0 mo.
-
Aug 01, 2025 23:59 UTC
debt
materiality 0.75
neutral
item 1.01item 2.03item 8.01item 9.01
Celcuity issues $201.25M of 2.750% convertible notes due 2031; net proceeds ~$194.5M
Issued $201.25M aggregate principal of 2.750% Convertible Senior Notes due 2031; initial conversion price ~$51.30/share.
-
Jul 31, 2025 23:59 UTC
other_material
materiality 0.70
neutral
item 1.01item 8.01item 9.01
Celcuity prices $175M convertible notes and stock offering; net proceeds ~$248.7M
$175M of 2.750% convertible senior notes due 2031 priced; initial conversion price ~$51.30/share (35% premium to stock offering).
-
Jul 29, 2025 23:59 UTC
other_material
materiality 0.85
neutral
item 1.01item 8.01item 9.01
Celcuity launches $150M convertible notes + $75M common stock offerings; also to draw $30M loan
Concurrent underwritten offerings: $150M convertible notes due 2031 and $75M common stock; 30-day over-allotment options for additional $22.5M notes and $11.25M stock.
-
Jul 28, 2025 23:59 UTC
other_material
materiality 0.95
positive
item 7.01item 8.01item 9.01
Celcuity Phase 3 VIKTORIA-1 PIK3CA wild-type: gedatolisib triplet cuts progression/death risk by 76% (HR 0.24)
Gedatolisib triplet (plus palbociclib/fulvestrant) mPFS 9.3 mo vs 2.0 mo for fulvestrant, incremental gain 7.3 mo.
-
Jun 30, 2025 23:59 UTC
other_material
materiality 0.75
positive
item 7.01item 8.01item 9.01
Celcuity reports 66% six-month rPFS in mCRPC Phase 1, 43% ORR in HER2+ mBC Phase 2
Phase 1 mCRPC (gedatolisib + darolutamide): 66% six-month rPFS; no treatment-related discontinuations or Grade 3 hyperglycemia; Grade 2-3 stomatitis in 10.5% of patients.